CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell...
Phase 2
Paris, France and 83 other locations
will receive, every three weeks, a dose of DS-1062a equivalent to 6 mg/kg of body weight until progression or until unacceptable toxicity.Tumor...
Phase 2
Paris, France and 8 other locations
type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...
Phase 1, Phase 2
Paris, France and 123 other locations
with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) wi...
Phase 2
Paris, France and 64 other locations
in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with o...
Phase 3
Paris, France and 209 other locations
over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non...
Phase 1
Villejuif Cedex, France and 38 other locations
PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC)....
Phase 2
Paris, France and 126 other locations
A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung...
Phase 2
Creteil, France and 138 other locations
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...
Phase 2
Paris, France and 123 other locations
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI...
Phase 3
Bobigny, Ile-de-France, France and 54 other locations
Clinical trials
Research sites
Resources
Legal